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Inhibition of acetylcholinesterase is considered as a promising approach for treatment of 
neurodegenerative disorders including Alzheimer's disease. In this study, we demonstrated that 5-
substituted N-phenacylthiazolium derivatives are capable of inhibiting acetylcholinesterase and 
butyrylcholinesterase activities with IC50 values in the micromolar range. Some of the new 
thiazolium-based inhibitiors showed more than 10-fold selectivity for butyrylcholinesterase. Kinetic 
experiments and molecular docking were performed for understanding the inhibition mechanisms. 
________________________________________________________________________________ 
1. Introduction 
Acetylcholinesterase (AChE) and 
butyrylcholinesterase (BChE) belong to a class 
of serine hydrolases and have 65% identity in 
amino acid sequences [1, 2]. The function of 
AChE is termination of nerve impulses at the 
cholinergic synapses through acetylcholine 
hydrolysis. Reduced amount of the 
acetylcholine, because of abnormal activity of 
сholine acetyltransferase [3, 4], along with 
extracellular deposits of β-amyloid in senile 
plaques is associated with cognitive function 
impairment in patients with Alzheimer's disease 
[5, 6]. According to the cholinergic hypothesis 
[7], consequences of the neurotransmitter deficit 
can be reduced by inhibition of AChE [5, 8]. 
Such approach is used in treatment of 
Alzheimer's disease and may be effective in 
Parkinson's disease and dementia with Lewy 
bodies [9-11]. The functions of BChE are still 
not fully understood. This enzyme is able to 
participate in fat metabolism [12], protect the 
AChE from inactivation by the anticholinergic 
agents [13], and compensate the lack of AChE 
activity [14, 15]. In addition, BChE is involved 
in the formation of amyloid plaques [16], and 
increased activity of the enzyme is observed in 
Alzheimer's disease [1, 17, 18]. 
2,4-Substituted thiazoles [19-21] 
including thiazole drug acotiamide [22] as well 
as derivatives of benzothiazole, [23, 24] 
thiazolopyrimidine, [25] and thiazolotriazinone 
[26, 27] can exhibit inhibitory properties against 
AChE and BChE. It should be noted that some 
of thiazolium salts may be considered as 
neuromuscular blocking agents [28, 29]. 
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Thiamine pyrophosphate and thiazolium salts 
were shown to break protein crosslinks (AGEs) 
[30-32]. Vitamin B1 (thiamine) and its 
derivatives are important regulators of 
metabolic processes in the central nervous 
system [33, 34] possessing a weak inhibitory 
action on cholinesterases [35]. 
We have suggested that the thiazolium 
scaffold may be used to design compounds with 
enhanced inhibitory potential against 
cholinesterases. In this paper, a series of N-
phenacyl-4-methyl-5-(2-substituted) thiazolium 
salts has been synthesized and tested for their 
ability of inhibiting acetylcholinesterase and 
butyrylcholinesterase in vitro. 
 
2. Results and discussion 
Chemistry 
Target N-phenacylthiazolium salts 5-17 
were obtained in two steps (Scheme 1). The 
synthetic procedure involves the preparation of 
compounds 4a-i by reaction of 5-(2-
hydroxyethyl)-4-methyl-1,3-thiazole (3) with 
the appropriate acyl chlorides [36-38]. Then, the 
O-acylated compounds were reacted with 
corresponding phenacyl bromides, giving 
thiazolium salts 5-17. Compound 2 was 
synthesized by quaternization of 4,5-dimethyl-
1,3-thiazole (1) [32]. 
 
Inhibitory activity 
The activities of the thiazolium salts were 
evaluated in vitro using AChE from E. 
electricus and BChE from equine serum. The 
 
Scheme 1. Synthesis of N-phenacylthiazolium salts 2, 5-17. 
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results in Table 1 show that the nature of R1 
substituent modulates inhibitory activity of the 
compounds tested. Thiazolium salts 2 and 5-10 
exhibited weak inhibitory effects on activity of 
AChE, while BChE was more inhibited, 
especially by compounds 6-9 bearing norbornyl, 
phenyl or 4-methoxyphenyl groups. Among 
them, the highest inhibitory activity toward 
BChE was observed for 5-(4-
methoxybenzoyloxyethyl) substituted 
thiazolium salt 9 (IC50 = 0.94 M) with more 
than 30-fold selectivity over AChE. 3-
Nitrophenyl derivatives 12-14 were found to be 
more potent inhibitors of both AChE and BChE 
as compared to their 4-nitrophenyl analogs 10-
11. Compound 14 exhibits IC50 of 0.85 M for 
AChE and IC50 of 1.4 M in case of BChE. 
Further modification of substituent R1 with 
morpholino groups did not improve 
significantly the inhibitory properties of 
compounds 15 and 16. Introduction of bromine 
atom as R2 resulted in decreasing the inhibitory 
effects of compounds 10 and 15 on AChE 
whereas the inhibitory ability of compounds 7 
 
Table 1. Compounds 2, 5-17 as inhibitors of cholinesterasesa,b,c 
№ R2 R1 
IC50, µM  
AChE BChE 
2 - - 52.0±12.8 59.7±9.9 
5 Br cyclopropanyl 59.2±14.9 66.7±14.1 
6 H bicyclo[2.2.1]heptane-1-yl 51.3±15.4 4.2±0.5 
7 Br phenyl 57.8±13.4 6.7±1.2 
8 H phenyl 44.2±6.3 4.5±0.9 
9 H 4-metoxyphenyl 33.1±7.9 0.94±0.28 
10 Br 4-nitrophenyl 22.0±4.9 15.7±4.6 
11 H 4-nitrophenyl 8.8±1.0 16.3±4.7 
12 Br 3-nitrophenyl 2.8±0.5 2.8±0.4 
13 H 3-nitrophenyl 2.7±0.6 2.4±0.5 
14 H 2-chlor-5-nitrophenyl 0.85±0.23 1.9±0.55 
15 Br 4-morpholino-3-nitrophenyl 22.9±3.7 1.0±0.18 
16 H 4-morpholino-3-nitrophenyl 7.7±1.2 2.1±0.44 
17 H 2,2-diphenylmethyl 10.4±0.99 0.14±0.03 
а IC50 values are the means of 2-3 assays ± standard deviations; b under assay conditions the substrates concentration 
were 0.1 mM and 0.5 mM for AChE and BChE, respectively; c The determined Km values were 0.31 mM (AChE) and 
0.26 mM (BChE). 
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and 12 was unchanged. Among the inhibitors 
tested, compound 17 demonstrated the most 
potent BChE inhibition (IC50 = 0.14 M) with 
more than 50-fold selectivity over AChE (IC50 = 
10.4 M). 
 
Figure 1. Dose-dependent curve of AChE inhibition by 
compound 14. 
 
Figure 2. Dose-dependent curve of BChE inhibition by 
compound 17. 
 
The dose-dependent curves of AChE and 
BChE inhibition by compounds 14 and 17 
showed in Figures 1 and 2, respectively. The 
Hill coefficient for the inhibition of AChE by 
compound 14 is 1.01 ± 0.13. This suggests that 
only one binding site on the enzyme molecule 
surface may be involved in the inhibition 
mechanism. In case of BChE the Hill coefficient 
was 1.48 ± 0.29 indicating possibility of more 
than one binding site for compound 17. 
A Lineweaver–Burk plot for inhibition 
of AChE by compound 14 (Figure 3) showed a 
mixed type mechanism. The calculated values 
of Ki and Ki' are 0.78 ± 0.09 µM and 2.11 ± 0.22 
µM, respectively. According to this, the 
compound binds to the free enzyme and the 
enzyme-substrate complex. The mixed type 
inhibition of AChE (Scheme 2) can include 
interaction of the inhibitor with covalent acyl-
enzyme intermediate, which results in block of 
the deacetylation step [39-41]. 
 
 
 
Figure 3. Lineweaver-Burk plots for inhibition of AChE 
by compound 14. Concentrations of the inhibitor were: □ 
- 0, ▲ – 0.4 µM, ○ – 0.6 µM and ■ – 1.2 µM. 
 
 
 
Scheme 2. Probable mechanism of AChE inhibition by 
compound 14. 
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Regarding BChE, Lineweaver-Burk 
reciprocal plot (Figure 4) showed that 
compound 17 is competitive inhibitor of the 
enzyme with Ki value of 0.098 ± 0.057 µM. 
This suggests that the inhibitor is positioned in 
the active site, preventing the substrate binding 
(Scheme 3). 
 
 
 
 
Figure 4. Lineweaver-Burk plots for inhibition of  BChE 
by compound 17. Concentration of the inhibitor were: □ - 
0, ▲ – 0.01 µM, ○ – 0.016 µM and ■ – 0.02 µM. 
 
 
 
Scheme 3. Mechanism of competitive inhibition of BChE 
by compound 17. 
 
It should be noted that rivastigmine, 
galantamine and donepezil are widely used 
today in symptomatic treatment of 
neurodegenerative diseases [7]. Rivastigmine 
exhibits a dual action with inhibiting both of the 
cholinesterases. Donepezil is more effective 
inhibitor of AChE, with lower activity against 
BChE [1]. In our experiments, IC50 values of 
donepezil were of 0.013 µM and 2.29 µM for 
AChE and BChE, respectively. 
 
Molecular docking 
Molecular docking calculations were 
carried out by using Autodock 4.2 in order to 
elucidate possible binding modes of the 
thiazolium derivatives with AChE and BChE. In 
case of compound 14, the inhibitor occupies the 
gorge of active site of AChE (Figure 5) with the 
estimated binding energy of -9.13 kcal/mol. The 
inhibitor is involved in aromatic-aromatic 
interactions with Trp86 in the anionic subsite as 
well as Trp286 in peripheral anionic site, and 
Phe338 at acyl binding pocket, which is 
consistent with the known mechanisms of 
AChE inhibition [42]. The oxygen atom of 
carbonyl group participates in hydrogen bonds 
with NH-groups of backbone chains of Phe295 
and Arg296. The NO2 group of the inhibitor 
forms H-bond with Tyr72 and Tyr124 whereas 
the chlorine atom has weak interaction with 
Ser293. 
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Figure 5. Possible binding mode of compound 14 at the 
active site of human AChE. 
 
In case of BChE, compound 20 occupies 
the anionic and esterase subsites (Figure 6) that 
is consistent with the mechanism of competitive 
inhibition. The binding energy was calculated to 
be -8.25 kcal/mol. N-Phenacyl fragment is 
located between Trp82 and His438, while 
carbonyl atom of oxygen forms hydrogen bonds 
with Trp82, Trp430, and Tyr440. The 
thiazolium ring of the inhibitor is close to 
Tyr332. One phenyl ring of the bulky 
diphenylmethyl fragment is located in esterase 
subsite and surrounded by Trp231, Leu286, 
Phe329, Phe398, and His438. Another phenyl 
ring is located close to Gly116 and Gly117 of 
the oxyanion hole. The hydrophobic, van der 
Waals, and electrostatic interactions can be 
important for stabilization of this enzyme-
inhibitor complex. 
 
 
 
Figure 6. Possible binding mode of compound 17 at the 
active site of human BChE. 
 
This study showed that 5-substituted N-
phenacylthiazolium derivatives 6-9, 15, and 17 
can selectively inhibit BChE as compared with 
AChE. The differences between the inhibition 
profiles can be interpreted on a structural basis. 
The catalytic sites of both enzymes are located 
at the bottom of the gorge on the depth of about 
20 Å and are surrounded at the exit by amino 
acid residues of peripheral anionic sites [43, 44]. 
Some of aromatic amino acid residues at the 
active site gorge of AChE are replaced by 
aliphatic ones in BChE [45]. Therefore, the acyl 
pocket of BChE is wider which enables to bind 
of bulky ligands [46] whereas AChE is 
structurally adapted to acetylcholine. According 
to this, acyl binding pocket of BChE 
accommodates phenyl ring of diphenylmethyl 
fragment of inhibitor 17 (Figure 6). The 
aromatic amino acid residues of Tyr72, Tyr124 
and Trp286 at the peripheral anionic site of 
AChE are represented by Asn68, Gln119 and 
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Ala277 in case of BChE, which also promotes 
the binding of bulky molecules. 
 
3. Conclusion 
We found that the derivatives 3-
phenacyl-4-methyl-5-substituted thiazolium 
salts can inhibit activity of BChE and AChE 
exhibiting micromolar IC50 values. The nature 
of substituent in position 5 of the thiazolium 
salts may influence sufficiently their inhibitory 
potency. Among the compounds tested, the best 
inhibitor of BChE with more then 50-fold 
selectivity over AChE was compound 17 
bearing bulky diphenylmethyl fragment (IC50 = 
0.14 M). Compound 14 with 2-chlor-5-
nitrophenyl moiety was found to be dual AChE 
and BChE inhibitors (IC50 of 0.85 M and 1.4 
M, respectively). Molecular docking results 
indicate that inhibitor 14 in the active site of 
AChE and compound 17 in the active site of 
BChE are stabilized by hydrogen bonds and 
hydrophobic interactions. The data obtained 
suggest that N-phenacylthiazolium salt can be 
promising scaffold for designing inhibitors of 
the cholinesterases. 
 
4. Materials and methods 
4.1. Chemistry 
1H NMR spectra were recorded on a 
Varian M400 (400 MHz/100 MHz) 
spectrometer in DMSO-d6. 4,5-
Dimethylthiazole (1) and 4-methyl-5-(2-
hydroxyethyl)thiazole (3) were commercially 
available and used after distillation. Compounds 
4a-i were prepared by reaction of 5-(2-
hydroxyethyl)-4-methyl-1,3-thiazole (3) with 
the appropriate acyl chlorides [36-38] in 
benzene in the presence of triethylamine. Acyl 
chlorides were produced by standard methods 
from corresponding carboxylic acids. Phenacyl 
bromide and p-bromophenacyl bromide were 
obtained from Sigma-Aldrich. 3-[2-(4-
Bromophenyl)-2-oxoethyl]-4,5-dimethyl-1,3-
thiazolium bromide 2 was synthesized as 
described previously [32]. 
 
4.1.1. General procedure for the synthesis of N-
phenacylthiazolium salts 5-17 
Synthesis of compounds 5-13, 17. Phenacyl 
bromide or p-bromophenacyl bromide (5 mmol) 
was added to a solution of 5 mmol of 4-methyl-
5-substituted thiazole (compounds 4a-f,i) in 
acetone. The reaction mixture was heated under 
reflux for 3-5 h. After that, the reaction was left 
standing at room temperature. The product was 
treated with acetone and diethyl ether, filtered 
and recrystallized from methanol-acetone-
diethyl ether mixture to give compounds 5-13, 
17. 
Synthesis of compounds 14-16. A mixture of 
phenacyl bromide or p-bromophenacyl bromide 
(5 mmol) and 5 mmol of 4-methyl-5-substituted 
thiazole (compounds 4g,h) was heated at 100-
110 oC for 1.5-3 h. After that, acetone and 
diethyl ether were added to wash the solidified 
product and the mixture left standing at room 
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temperature. The product was recrystallized 
from methanol-acetone or i-propanol to give 
compounds 14-16. 
 
3-[2-(4-bromophenyl)-2-oxoethyl]-4,5-dimethyl-
1,3-thiazolium bromide (2). Yield of 65 %, a 
white solid, m.p. 189–191 °C; 1H NMR 
(DMSO-d6, 400 MHz, δ, ppm): 9.98 (s, 1H), 
7.99 (d, 2H, J = 8.4 Hz), 7.88 (d, 2H, J = 8.4 
Hz), 6.41 (s, 2H), 2.53 (s, 3H), 2.31 (s, 3H). 
Anal. calсd. for C13H13Br2NOS: C, 39.92; H, 
3.35; N, 3.58; S, 8.20. Found: C, 39.99; H, 3.44; 
N, 3.59; S, 8.35. 
 
3[2-(4-bromophenyl)-2-oxoethyl]-5-{2-
[(cyclopropylcarbonyl)oxy]ethyl}-4-methyl-1,3-
thiazolium bromide (5). Yield of 52 %, a white 
solid, m.p. 176–178 °C; 1H NMR (DMSO-d6, 
400 MHz, δ, ppm): 10.03 (s, 1H), 7.99 (d, 2H, J 
= 8.7 Hz), 7.89 (d, 2H, J = 8.7 Hz), 6.40 (s, 2H), 
4.25 (t, 2H, J = 5.6 Hz), 3.33 (t, 2H, J = 5.6 Hz), 
2.36 (s, 3H), 1.65-1.59 (m, 1H), 0.92-0.82 (m, 
4H). Anal. calсd. for C18H19Br2NO3S: C, 44.19; 
H, 3.91; N, 2.86; S, 6.55. Found: C, 44.43; H, 
3.93; N, 2.81; S, 6.43. 
 
5-{2-[(bicyclo[2.2.1]hept-1-
ylcarbonyl)oxy]ethyl}-4-methyl-3-(2-oxo-2-
phenylethyl)-1,3-thiazolium bromide (6). Yield 
of 56 %, a white solid, m.p. 180–182 °C; 
1H NMR (DMSO-d6, 400 MHz, δ, ppm): 10.05 
(s, 1H), 8.06 (d, 2H, J = 7.5 Hz), 7.79 (t, 1H, J = 
7.5 Hz), 7.65 (t, 2H, J = 7.5 Hz), 6.44 (s, 2H), 
4.28 (t, 2H, J = 5.6 Hz), 3.33 (t, 2H, J = 5.6 Hz), 
2.36 (s, 3H), 2.27 (s, 1H), 1.82-1.75 (m, 2H), 
1.67-1.62 (m, 2H), 1.50-1.45 (m, 4H), 1.35-1.26 
(m, 2H). Anal. calсd. for C22H26BrNO3S: C, 
56.90; H, 5.64; N, 3.02; S, 6.89. Found: C, 
56.94; H, 5.75; N, 3.11; S, 6.95. 
 
5-[2-(benzoyloxy)ethyl]-3-[2-(4-bromophenyl)-
2-oxoethyl]-4-methyl-1,3-thiazolium bromide 
(7). Yield of 60 %, a white solid, m.p. 190–192 
°C; 1H NMR (DMSO-d6, 400 MHz, δ, ppm): 
10.01 (s, 1H), 7.99-7.96 (m, 4H), 7.88 (d, 2H, J 
= 8.4 Hz), 7.69 (t, 1H, J = 7.5 Hz), 7.55 (t, 2H, J 
= 7.5 Hz), 6.38 (s, 2H), 4.52 (t, 2H, J = 5.6 Hz), 
3.48 (t, 2H, J = 5.6 Hz), 2.38 (s, 3H). Anal. 
calсd. for C21H19Br2NO3S: C, 48.02; H, 3.65; N, 
2.67; S, 6.10. Found: C, 48.37; H, 3.74; N, 2.75; 
S, 6.52. 
 
5-[2-(benzoyloxy)ethyl]-4-methyl-3-(2-oxo-2-
phenylethyl)-1,3-thiazolium bromide (8). Yield 
of 58 %, a white solid, m.p. 180–182 °C; 
1H NMR (DMSO-d6, 400 MHz, δ, ppm): 10.06 
(s, 1H), 8.06 (d, 2H, J = 7.5 Hz), 7.99 (d, 2H, J 
= 7.5 Hz), 7.78 (t, 1H, J = 7.5 Hz), 7.70-7.63 
(m, 3H), 7.55 (t, 2H, J = 7.5 Hz), 6.44 (s, 2H), 
4.53 (t, 2H, J = 5.6 Hz), 3.49 (t, 2H, J = 5.6 Hz), 
2.39 (s, 3H). Anal. calсd. for C21H20BrNO3S: C, 
56.51; H, 4.52; N, 3.14; S, 7.18. Found: C, 
56.67; H, 4.43; N, 3.24; S, 7.19. 
 
5-{2-[(4-methoxybenzoyl)oxy]ethyl}-4-methyl-3-
(2-oxo-2-phenylethyl)-1,3-thiazolium bromide 
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(9). Yield of 70 %, a white solid, m.p. 199–201 
°C; 1H NMR (DMSO-d6, 400 MHz, δ, ppm): 
10.05 (s, 1H), 8.06 (d, 2H, J = 7.5 Hz), 7.94 (d, 
2H, J = 9.3 Hz), 7.79 (t, 1H, J = 7.5 Hz), 7.65 (t, 
2H, J = 7.5 Hz), 7.06 (d, 2H, J = 8.4 Hz), 6.43 
(s, 2H), 4.49 (t, 2H, J = 5.6 Hz), 3.83 (s, 3H), 
3.46 (t, 2H, J = 5.6 Hz), 2.38 (s, 3H). Anal. 
calсd. for C22H22BrNO4S: C, 55.47; H, 4.65; N, 
2.94; S, 6.73. Found: C, 55.69; H, 4.73; N, 2.89; 
S, 7.07. 
 
3-[2-(4-bromophenyl)-2-oxoethyl]-4-methyl-5-
{2-[(4-nitrobenzoyl)oxy]ethyl}-1,3-thiazolium 
bromide (10). Yield of 55 %, a white solid, m.p. 
228–230 °C; 1H NMR (DMSO-d6, 400 MHz, δ, 
ppm): 10.01 (s, 1H), 8.36 (d, 2H, J = 8.4 Hz), 
8.20 (d, 2H, J = 8.4 Hz), 7.97 (d, 2H, J = 8.4 
Hz), 7.88 (d, 2H, J = 8.4 Hz), 6.37 (s, 2H), 4.58 
(t, 2H, J = 5.6 Hz), 3.50 (t, 2H, J = 5.6 Hz), 2.38 
(s, 3H). Anal. calсd. for C21H18Br2N2O5S: C, 
44.23; H, 3.18; N, 4.91; S, 5.63. Found: C, 
44.46; H, 3.23; N, 5.04; S, 5.74. 
 
4-methyl-5-{2-[(4-nitrobenzoyl)oxy]ethyl}-3-(2-
oxo-2-phenylethyl)-1,3-thiazolium bromide (11). 
Yield of 51 %, a white solid, m.p. 220–221 °C; 
1H NMR (DMSO-d6, 400 MHz, δ, ppm): 10.10 
(s, 1H), 8.37 (d, 2H, J = 9.3 Hz), 8.20 (d, 2H, J 
= 8.4 Hz), 8.06 (d, 2H, J = 7.5 Hz), 7.78 (t, 1H, 
J = 7.5 Hz), 7.65 (t, 2H, J = 7.5 Hz), 6.47 (s, 
2H), 4.59 (t, 2H, J = 5.6 Hz), 3.52 (t, 2H, J = 5.6 
Hz), 2.39 (s, 3H). Anal. calсd. for 
C21H19BrN2O5S: C, 51.33; H, 3.90; N, 5.70; S, 
6.53. Found: C, 51.56; H, 3.96; N, 5.71; S, 6.62. 
 
3-[2-(4-bromophenyl)-2-oxoethyl]-4-methyl-5-
{2-[(3-nitrobenzoyl)oxy]ethyl}-1,3-thiazolium 
bromide (12). Yield of 58 %, a white solid, m.p. 
204–206 °C; 1H NMR (DMSO-d6, 400 MHz, δ, 
ppm): 10.03 (s, 1H), 8.64 (s, 1H), 8.53 (d, 1H, J 
= 7.5 Hz), 8.38 (d, 1H, J = 7.5 Hz), 7.95 (d, 2H, 
J = 8.4 Hz), 7.87 (t, 3H, J = 7.5 Hz) 6.39 (s, 
2H), 4.60 (t, 2H, J = 5.6 Hz), 3.52 (t, 2H, J = 5.6 
Hz), 2.39 (s, 3H). Anal. calсd. for 
C21H18Br2N2O5S: C, 44.23; H, 3.18; N, 4.91; S, 
5.63. Found: C, 44.90; H, 3.12; N, 4.66; S, 5.81. 
 
4-methyl-5-{2-[(3-nitrobenzoyl)oxy]ethyl}-3-(2-
oxo-2-phenylethyl)-1,3-thiazolium bromide (13). 
Yield of 57 %, a white solid, m.p. 187–190 °C; 
1H NMR (DMSO-d6, 400 MHz, δ, ppm): 10.06 
(s, 1H), 8.64 (s, 1H), 8.53 (d, 1H, J = 8.4 Hz), 
8.38 (d, 1H, J = 7.5 Hz), 8.03 (d, 2H, J = 7.5 
Hz), 7.87 (t, 1H, J = 7.5 Hz), 7.78 (t, 1H, J = 7.5 
Hz), 7.64 (t, 2H, J = 7.5 Hz), 6.43 (s, 2H), 4.60 
(t, 2H, J = 5.6 Hz), 3.53 (t, 2H, J = 5.6 Hz), 2.40 
(s, 3H). Anal. calсd. for C21H19BrN2O5S: C, 
51.33; H, 3.90; N, 5.70; S, 6.53. Found: C, 
51.47; H, 3.98; N, 5.53; S, 6.60. 
 
5-{2-[(2-chloro-5-nitrobenzoyl)oxy]ethyl}-4-
methyl-3-(2-oxo-2-phenylethyl)-1,3-thiazolium 
bromide (14). Yield of 65 %, a light yellow 
solid, m.p. 177–178 °C; 1H NMR (DMSO-d6, 
400 MHz, δ, ppm): 10.16 (s, 1H), 8.61 (d, 1H, J 
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= 2.8 Hz), 8.41 (dd, 1H, J = 9.3, 2.8 Hz), 8.03 
(d, 2H, J = 7.5 Hz), 7.92 (d, 1H, J = 8.4, Hz), 
7.78 (t, 1H, J = 7.5 Hz), 7.64 (t, 2H, J = 7.5 Hz), 
6.49 (s, 2H), 4.60 (t, 2H, J = 5.6 Hz), 3.52 (t, 
2H, J = 5.6 Hz), 2.39 (s, 3H). Anal. calсd. for 
C21H18BrClN2O5S: C, 47.97; H, 3.45; N, 5.33; 
S, 6.10. Found: C, 48.24; H, 3.54; N, 5.45; S, 
6.15. 
 
3-[2-(4-bromophenyl)-2-oxoethyl]-4-methyl-5-
{2-[(4-morpholin-4-yl-3-
nitrobenzoyl)oxy]ethyl}-1,3-thiazolium bromide 
(15). Yield of 40 %, a yellow solid, m.p. 175–
177 °C; 1H NMR (DMSO-d6, 400 MHz, δ, 
ppm): 10.06 (s, 1H), 8.30 (s, 1H), 8.04 (d, 1H, J 
= 8.4), 7.97 (d, 2H, J = 7.5), 7.87 (d, 2H, J = 8.4 
Hz), 7.37 (d, 1H, J = 8.4 Hz), 6.41 (s, 2H), 4.53 
(t, 2H, J = 5.6 Hz), 3.70 (s, 4H), 3.48 (t, 2H, J = 
5.6 Hz), 3.16 (s, 4H), 2.38 (s, 3H). Anal. calсd. 
for C25H25Br2N3O6S: C, 45.82; H, 3.85; N, 6.41; 
S, 4.89. Found: C, 45.93; H, 3.89; N, 6.38; S, 
4.78. 
 
4-methyl-5-{2-[(4-morpholin-4-yl-3-
nitrobenzoyl)oxy]ethyl}-3-(2-oxo-2-
phenylethyl)-1,3-thiazolium bromide (16). Yield 
of 43 %, a yellow solid, m.p. 178–180 °C; 
1H NMR (DMSO-d6, 400 MHz, δ, ppm): 10.06 
(s, 1H), 8.31 (s, 1H), 8.04 (d, 3H, J = 7.5 Hz), 
7.78 (t, 1H, J= 7.5 Hz), 7.65 (t, 2H, J = 7.5 Hz) 
7.38 (d, 1H, J = 9.3 Hz) 6.42 (s, 2H), 4.53 (t, 
2H, J = 5.6 Hz), 3.70 (t, 4H, J = 4.7 Hz), 3.49 (t, 
2H, J = 5.6 Hz), 3.16 (t, 4H, J = 4.7 Hz), 2.38 
(s, 3H). Anal. calсd. for C25H26BrN3O6S: C, 
52.09; H, 4.55; N, 7.29; S, 5.56. Found: C, 
51.98; H, 4.51; N, 7.21; S, 5.52. 
 
5-{2-[(diphenylacetyl)oxy]ethyl}-4-methyl-3-(2-
oxo-2-phenylethyl)-1,3-thiazolium bromide (17). 
Yield of 70 %, a white solid, m.p. 165–167 °C; 
1H NMR (DMSO-d6, 400 MHz, δ, ppm): 9.97 
(s, 1H), 8.08 (d, 2H, J = 7.5 Hz), 7.80 (t, 1H, J = 
7.5 Hz), 7.67 (t, 2H, J = 7.5 Hz), 7.35-7.24 (m, 
10H), 6.35 (s, 2H), 5.19 (s, 1H), 4.36 (t, 2H, J = 
6.0 Hz), 3.31 (t, 2H, J = 6.0 Hz), 2.23 (s, 3H). 
Anal. calсd. for C28H26BrNO3S: C, 62.69; H, 
4.88; N, 2.61; S, 5.98. Found: C, 62.83; H, 4.95; 
N, 2.70; S, 6.06. 
 
4.2. In vitro study of acetylcholinesterase and 
butyrylcholinesterase inhibition 
Acetylcholinesterase from E. electricus, 
butyrylcholinesterase from equine serum and 
Ellman's reagent (DTNB) were purchased from 
Sigma-Aldrich. S-Acetylthiocholine iodide and 
S-butyrylthiocholine iodide from Sigma-Aldrich 
and Fluka, respectively, were used as substrates. 
The inhibitory activities of compounds were 
determined by modified Ellman's method [47]. 
Spectrophotometric study was performed at a 
wavelength of 412 nm. 
Reaction mixture was consisted of 25 
mM phosphate buffer (pH 7.48), 0.1 mM S-
acetylthiocholine iodide, 1 mM DTNB, 1 % 
dimethyl sulfoxide (DMSO), water, and 
inhibitor. Before used in the experiments, the 
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tested compounds 2 and 5-17 were dissolved in 
DMSO and then were diluted with water to the 
required concentration. The prepared mixture 
was incubated during 5 minutes at 25°C and 
substrate hydrolysis was started by adding the 
enzyme. The inhibitory activity of thiazolium 
salts toward BChE was study in similar assay 
conditions with the concentration of S-
butyrylthiocholine iodide of 0.5 mM. 
The Hill coefficients (values ± standard 
error) for compounds 14 and 17 were calculated 
from dose-dependent inhibition curves (Figures 
1 and 2) with using of four parameters equation. 
The values of IC50 (Table 1) were the 
concentration of inhibitor which reduces 
enzyme activity by 50 %. The kinetic data of 
enzymatic transformation of S-acetylthiocholine 
iodide and S-butyrylthiocholine iodide in the 
absence and presence of compounds 16 and 20 
were analyzed from Lineweaver-Burk plots 
(Figures 3 and 4). The molar extinction 
coefficient of 5-thio-2-nitrobenzoate (TNB2-) of 
14150 M-1cm-1 was used [48] for calculation. 
Selectivity index (IC50 of AChE/IC50 of 
BChE) was estimated using the recalculated 
IC50 values [49] for BChE at 0.1 mM substrate 
concentration assuming competitive inhibition. 
 
4.3. Molecular docking 
Molecular docking was performed by 
using Autodock 4.2 program. The compound 14 
was docked to the active site of A chain of 
human AChE (PDB code 4EY7 [50]). The 
compound 17 was docked to the active site 
gorge of human BChE (PDB code 4BDS [51]). 
Before starting the docking calculations, ligands 
and water molecules were removed from initial 
PDB crystals. The structures of inhibitors were 
optimized by AM1 semi-empirical quantum 
mechanical method in program MOPAC. 
MGLTools was used to prepare the docking 
files. The most probable binding modes were 
predicted by using the Lamarckian genetic 
algorithm (LGA) method. 
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